Aurobindo Pharma's Subsidiary Acquires Khandelwal Labs' Business for ₹3,250 Million

Aurobindo Pharma's subsidiary, Auro Pharma Ltd, has acquired Khandelwal Laboratories' branded non-oncology prescription formulations business for ₹3,250 million. The deal, effective January 1, 2026, includes 23 brands in anti-infective and pain management, with the acquired business recording ₹1,135.3 million turnover in FY24-25, leading to a positive uptick in Aurobindo Pharma's stock.